The FDA, urged to avoid controversy, creates a new headache with attack against UniQure – statnews.com
There was a telling exchange during a Thursday media call set up by the Food and Drug Administration to enable a “senior FDA official” — he could only be quoted anonymously — to attack UniQure and its experimental treatment for Huntington’s disease.
Robert Langreth, a reporter for Bloomberg, asked the senior official how long he planned to stay at the FDA.
The FDA official responded, “You all know that as background, I’m a professor and I’m a practicing [hematology-oncology] doctor. I do miss my clinic and I miss teaching, and I miss being able to run my podcast and speak freely. But I would say that I serve at the pleasure of the [FDA] commissioner and the [health] secretary and the president, and as long as we’re all in alignment — that me serving is in the best interest of the American people — I will continue to serve happily.”
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
